T. Petrella

发表

A network approach to developing immuno-oncology combinations in Canada.

H. McArthur, S. Verma, G. Batist, 2019, Current oncology.

To ban or not to ban tanning bed use for minors: A cost‐effectiveness analysis from multiple US perspectives for invasive melanoma

D. Goldstein, K. Marqueen, B. Ferket, 2021, Cancer.

Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review.

G. Fletcher, E. McWhirter, T. Baetz, 2020, Cancer treatment reviews.

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.

V. Sondak, J. Sosman, J. Kirkwood, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin-21 has activity in patients with metastatic melanoma: a phase II study.

Bingshu E. Chen, K. Savage, K. Bélanger, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Utility of adjuvant systemic therapy in melanoma

A. Hauschild, A. Eggermont, A. Testori, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Temozolomide for the treatment of metastatic melanoma

S. Verma, T. Petrella, M. Charette, 2007, Current oncology.

Erratum to: Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease

A. Baccarelli, F. Nordio, S. Kamel‐Reid, 2014, Annals of Surgical Oncology.

Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease

A. Baccarelli, F. Nordio, S. Kamel‐Reid, 2014, Annals of Surgical Oncology.

Primary excision margins and sentinel lymph node biopsy in clinically node-negative melanoma of the trunk or extremities.

D. McCready, F. Wright, C. Murray, 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

Cost‐effectiveness analysis of staging strategies in patients with regionally metastatic melanoma

Kelvin K. W. Chan, N. L. Look Hong, T. Petrella, 2015, Journal of surgical oncology.

The Cardiac Rehabilitation Model Improves Fitness, Quality of Life, and Depression in Breast Cancer Survivors

S. Marzolini, L. Dolan, D. Barry, 2017, Journal of cardiopulmonary rehabilitation and prevention.

Melanoma

D. McCready, A. Covelli, J. Lipa, 2020, Surgical Oncology Manual.

Melanoma of the Vulva and Vagina: Surgical Management and Outcomes Based on a Clinicopathologic Reviewof 68 Cases.

S. Sinasac, D. Vicus, D. Ghazarian, 2019, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Primary excision margins, sentinel lymph node biopsy, and completion lymph node dissection in cutaneous melanoma: a clinical practice guideline.

D. McCready, F. Wright, C. Nessim, 2019, Current oncology.

Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series

F. Wright, N. L. Look Hong, T. Petrella, 2017, Expert review of clinical immunology.

Exercise for people with cancer: a systematic review.

J. Tomasone, E. Green, A. Loblaw, 2017, Current oncology.

Exercise for people with cancer: a clinical practice guideline.

J. Tomasone, E. Green, A. Loblaw, 2017, Current oncology.

Impact of a novel prioritization framework on clinician-led oncology drug submissions.

A. Finelli, A. Eisen, G. Darling, 2019, Current oncology.

Biochemotherapy for the treatment of metastatic malignant melanoma: a clinical practice guideline

S. Verma, C. Hamm, T. Petrella, 2008, Current oncology.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006.

J. Larkin, A. Ribas, C. Blank, 2016 .

Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy

S. Luoh, G. Hortobagyi, L. Vahdat, 2010, Breast Cancer Research and Treatment.

Restructuring Skin Cancer Care in Ontario: A Provincial Plan

A. Chan, J. Irish, F. Wright, 2021, Current oncology.

Mental health services use by melanoma patients receiving adjuvant interferon: association of pre-treatment mental health care with early discontinuation.

C. Earle, E. Eisenhauer, C. Booth, 2017, Current oncology.

Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy.

Kelvin K. W. Chan, J. Barfett, A. Yan, 2018, International journal of cardiology.

Serial Measurements of Left Ventricular Systolic and Diastolic Function by Cardiac Magnetic Resonance Imaging in Patients with Early Stage Breast Cancer on Trastuzumab.

Kelvin K. W. Chan, J. Barfett, A. Yan, 2019, The American journal of cardiology.

Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review.

I. Quirt, S. Verma, T. Petrella, 2007, Cancer treatment reviews.

Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?

N. Khushalani, C. Lao, T. Petrella, 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.

V. Sondak, J. Sosman, J. Kirkwood, 2017 .

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada

Kelvin K. W. Chan, C. Earle, N. Mittmann, 2020, BMC Cancer.

Perspectives

N. Hainc, I. Quirt, S. Verma, 2010, American Journal of Neuroradiology.

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

A. Carneiro, G. Long, L. Ny, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.

V. Sondak, J. Sosman, J. Kirkwood, 2019, Journal of Clinical Oncology.

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

James R. Anderson, J. Larkin, A. Ribas, 2018 .

Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006

N. Ibrahim, A. Ribas, C. Blank, 2017 .

Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.

G. Fletcher, E. McWhirter, T. Baetz, 2020, Current oncology.

Locoregional management of in-transit metastasis in melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.

C. Giacomantonio, A. Sun, F. Wright, 2020, Current oncology.

Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study.

G. Dranitsaris, M. Clemons, M. Trudeau, 2007, The journal of supportive oncology.

Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.

J. Larkin, A. Ribas, C. Blank, 2020 .

A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13.

Bingshu E. Chen, K. Savage, J. Dancey, 2018 .

Patient indications for Mohs micrographic surgery: a clinical practice guideline.

N. Solish, C. Murray, S. Bradshaw, 2019, Current oncology.

Patient Indications for Mohs Micrographic Surgery: A Systematic Review

N. Solish, C. Murray, S. Bradshaw, 2018, Journal of cutaneous medicine and surgery.

Patient Indications for Mohs Micrographic Surgery

N. Solish, C. Murray, S. Bradshaw, 2018 .

Treatment of primary cutaneous apocrine carcinoma of the scalp - case and review of the literature

M. Riesco-Martinez, T. Petrella, Zachary Brown, 2016 .

Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100

T. Vogel, I. Astsaturov, D. Spaner, 2006, Cancer.

Metastatic melanoma: optimizing outcomes by managing dermatologic toxicities associated with novel therapies.

V. Ho, T. Petrella, J. Claveau, 2014, Skin therapy letter.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

A. Ribas, C. Blank, A. Arance, 2017, The Lancet.

Curative Stereotactic Ablative Radiotherapy for a Locally Advanced Basal Cell Carcinoma in an Elderly Patient.

Justin W. Lee, I. Menjak, T. Petrella, 2018, Journal of oncology practice.

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

J. Larkin, A. Ribas, C. Blank, 2019, The Lancet. Oncology.

Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines.

I. Astsaturov, D. Spaner, N. Iscoe, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Impact of biomarkers on clinical trial risk in breast cancer

G. Lopes, R. Dent, T. Petrella, 2012, Breast Cancer Research and Treatment.

Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer.

K. Gelmon, J. Baselga, J. Cortes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.

R. Alkallas, P. Siegel, I. Watson, 2022, Cell reports.

Translocation (21;22)(q22;q12) in a Ewing sarcoma. New case characterized by cytogenetic analysis and fluorescence in situ hybridization of a fresh tumor.

F. Mugneret, T. Petrella, M. Flesh, 1996, Cancer genetics and cytogenetics.

Canadian Perspective on the Clinical Management of Metastatic Melanoma

M. Smylie, A. Spatz, S. Ernst, 2012 .

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

C. Berking, A. Hauschild, D. Schadendorf, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The clinical significance of indeterminate pulmonary nodules in melanoma patients at baseline and during follow-up chest CT

F. Wright, P. Tyrrell, A. Oikonomou, 2019, European journal of radiology open.

Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients

W. Miller, M. Butler, R. Gniadecki, 2021, Cancers.

Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review.

S. Verma, C. Hamm, T. Petrella, 2008, Cancer treatment reviews.

Single-agent interleukin-2 in the treatment of metastatic melanoma

I. Quirt, S. Verma, T. Petrella, 2007, Current oncology.

Immunotherapy of distant metastatic disease

A. Hauschild, D. Schadendorf, A. Eggermont, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Temozolomide for the treatment of metastatic melanoma: a systematic review.

I. Quirt, S. Verma, T. Petrella, 2007, The oncologist.

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.

W. Miller, N. Ibrahim, C. Robert, 2017, European journal of cancer.

Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.

S. Verma, E. Warner, A. Eisen, 2018, The oncologist.

Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline.

D. McCready, I. Quirt, S. Verma, 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients

G. Dranitsaris, M. Clemons, S. Chia, 2009, Breast Cancer Research and Treatment.

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

V. Sondak, J. Sosman, J. Kirkwood, 2021, Journal for ImmunoTherapy of Cancer.

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

K. Gelmon, J. Baselga, J. Albanell, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KIT Gene Mutations and Patterns of Protein Expression in Mucosal and Acral Melanoma

A. Seth, F. Wright, W. Hanna, 2012, Journal of cutaneous medicine and surgery.

Burden of illness for metastatic melanoma in Canada, 2011-2013.

M. Thabane, A. Joshua, F. Gwadry-Sridhar, 2016, Current oncology.

Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma

S. Ahmed, T. Petrella, J. Rauw, 2012, Medical Oncology.

Real‐world, population‐based cohort study of toxicity and resource utilization of second‐line ipilimumab for metastatic melanoma in Ontario, Canada

Kelvin K. W. Chan, C. Earle, N. Mittmann, 2020, International journal of cancer.

Motivation and preferences of exercise programmes in patients with inoperable metastatic lung cancer: a need assessment

S. Cheng, A. Kartolo, T. Petrella, 2015, Supportive Care in Cancer.

Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study

Kelvin K. W. Chan, J. Barfett, A. Yan, 2019, The International Journal of Cardiovascular Imaging.

A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial

K. Savage, K. Bélanger, E. Eisenhauer, 2008, Investigational New Drugs.

Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma.

V. Sondak, M. Knopp, J. Kirkwood, 2021, Cancer discovery.

Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM).

Bingshu E. Chen, K. Savage, K. Bélanger, 2010 .

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis.

V. Sondak, J. Kirkwood, F. Hodi, 2020 .

Radiotherapy to control CNS lymphomatoid granulomatosis: A case report and review of the literature

B. Leber, Glenn W. Jones, T. Petrella, 1999, American journal of hematology/oncology.

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization

C. Earle, N. Mittmann, R. Croxford, 2023, Cancer medicine.

Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.

J. Larkin, A. Ribas, C. Blank, 2017 .

Temozolomide for the Treatment of Metastatic Melanoma: A Practice Guideline

I. Quirt, S. Verma, T. Petrella, 2007 .

LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004

A. Carneiro, G. Long, L. Ny, 2020 .

Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

James R. Anderson, J. Larkin, A. Ribas, 2019, Clinical Trials.

Surveillance After a Previous Cutaneous Melanoma Diagnosis: A Scoping Review of Melanoma Follow-Up Guidelines

R. Alhusayen, I. Mukovozov, T. Petrella, 2023, Journal of cutaneous medicine and surgery.

Cost‐effectiveness analysis of staging strategies in patients with regionally metastatic melanoma

Kelvin K. W. Chan, N. L. Look Hong, T. Petrella, 2015, Journal of Surgical Oncology.

Phase II study of sagopilone (ZK-Epo) in patients with recurrent metastatic breast cancer (MBC).

S. Luoh, G. Hortobagyi, L. Vahdat, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements

K. Savage, W. Miller, T. Petrella, 2021, Current oncology.

Resource utilization and costs of managing patients with advanced melanoma: a Canadian population-based study.

N. Mittmann, A. Joshua, F. Gwadry-Sridhar, 2017, Current oncology.

A pilot study of the neoadjuvant use of vemurafenib plus cobimetinib in patients with BRAF-mutant melanoma with palpable lymph node metastases: Survival results.

F. Wright, I. Watson, C. Nessim, 2023, Journal of Clinical Oncology.

Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.

A. Carneiro, A. Arance, G. Long, 2021, Journal of Clinical Oncology.

Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma

A. Ribas, J. Schachter, J. Grob, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of a Multidisciplinary Immunotherapy Toxicity Monitoring Program for Patients Receiving Ipilimumab for Metastatic Melanoma

T. Petrella, D. Lawrie, S. Jain, 2021, JCO oncology practice.

Resource utilization and disaggregated cost analysis for initial treatment of melanoma

C. Earle, F. Wright, N. Mittmann, 2017, Journal of Cancer Policy.